---
title: "Turn Therapeutics releases corporate deck outlining GX-03 topical immunomodulator program for atopic dermatitis"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294063417.md"
description: "Turn Therapeutics released a corporate deck detailing its GX-03 topical immunomodulator program for atopic dermatitis. GX-03 targets IL-36 and downstream cytokines. Phase 2 trials are ongoing, with topline results expected in Q4 2026. Interim data showed significant efficacy compared to vehicle. The company plans an FDA meeting in Q4 2026 and aims to initiate Phase 3 trials by mid-2027."
datetime: "2026-07-28T12:09:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294063417.md)
  - [en](https://longbridge.com/en/news/294063417.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294063417.md)
generator: "portal-rs"
---

# Turn Therapeutics releases corporate deck outlining GX-03 topical immunomodulator program for atopic dermatitis

-   Turn Therapeutics highlighted GX-03, a topical, non-systemic immunomodulator targeting IL-36 and downstream cytokines, with initial focus on moderate-to-severe atopic dermatitis. \* Phase 2 randomized trial in atopic dermatitis remains in progress; topline results are expected in Q4 2026. \* Stage 1 completed in June 2026 with 50 patients; Stage 2 targets about 120-135 patients in an adaptive, vehicle-controlled design. \* Interim subgroup showed Week 4 vIGA-AD success of 61.5% for GX-03 versus 8.3% for vehicle; p=0.01. \* Pipeline milestones include a Type B FDA meeting in Q4 2026; Phase 3 initiation targeted for mid-2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TTRX.US](https://longbridge.com/en/quote/TTRX.US.md)

## Related News & Research

- [Turn Therapeutics says mouse study shows GX-03 cuts dermatitis severity 66%](https://longbridge.com/en/news/296487429.md)
- [Turn Therapeutics sells 135,000 shares in private placement for $1.35 million](https://longbridge.com/en/news/296141997.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Robo.ai COO Chaoyin Xie files initial beneficial ownership statement](https://longbridge.com/en/news/296381712.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**